Table 2.

Multivariable analysis of impact of high-dose [>12.5 mg] or low-dose MTX [≤12.5 mg] on efficacy and safety outcomes in patients with inflammatory bowel diseases

	OR†	95% CI	p-value
Side effects	1.59	0.77–3.31	0.21
Serious infections	1.19	0.41–3.45	0.75
Remission at 1 year	1.02	0.47–2.22	0.97
Hospitalization within 1 year	0.42	0.17–1.04	0.06
Surgery within 1 year	0.46	0.14–1.47	0.19
Combined outcomes‡	0.49	0.23–1.04	0.06

^†High-dose compared with low-dose MTX [reference].

^‡Composite outcome included switch of biologic therapy, hospitalization within 1 year, surgery within 1 year, and steroid therapy initiated in the first year